Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25740
Title: A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
Austin Authors: Gan, Hui K ;Burge, Matthew;Solomon, Benjamin;Lee, Sze Ting ;Holen, Kyle D;Zhang, Yumin;Ciprotti, Marika;Lee, F T;Manusinghe, Wijth;Fischer, Judee;Ansell, Peter;Fox, Gerard;Xiong, Hao;Reilly, Edward B;Humerickhouse, Rod;Scott, Andrew M 
Affiliation: Peter MacCallum Cancer Centre, Australia
Olivia Newton-John Cancer Research Institute
Royal Brisbane and Women's Hospital, Australia
Abbvie, United States
Sinotau Pharmaceutical Group, China
Issue Date: 28-Jan-2021
metadata.dc.date: 2021-01-28
Publication information: Journal of Nuclear Medicine 2021; online first: 28 January
Abstract: ABT-806 is a tumor-specific antibody targeting the epidermal growth factor receptor (EGFR). This study assessed safety, biodistribution and pharmacokinetics of indium-111 (111In) radiolabeled ABT-806 (ABT-806i) and effects of repeated doses of ABT-806 on receptor occupancy. Methods: Eligible patients had advanced tumors likely to express EGFR/EGFRvIII; adequate performance status and organ function; and measurable disease by RECIST 1.1. In Cohort 1, 6 patients received a bolus administration of ABT-806i and underwent single-photon emission computed tomography (SPECT) followed by whole body planar scans. In Cohort 2, 12 patients were imaged similarly as in 1 initially; thereafter they received three doses of unlabelled ABT-806, before another dose of ABT-806i with associated SPECT and whole body planar scans. At the end of both cohorts, patients who had stable or responding disease were able to enroll into an extension study (M12-326) where they received unlabelled ABT-806 every 2 weeks until disease progression, withdrawal of consent or intolerable toxicity Results: No toxicity related to ABT-806i infusion were observed. ABT-806i showed minimal uptake in normal tissues and cleared gradually from blood with t½ of 6.0 + 1.5 days. The mean effective dose of ABT-806i was determined as 0.137 mSv/MBq for males and 0.183 mSv/MBq for females. ABT-806i tumor uptake varied and did not correlate with archived tumor EGFR expression. No change in ABT-806i uptake was observed after interval ABT-806 treatment, indicating stable EGFR expression in tumor. The patient with highest tumor uptake of ABT-806i had advanced head and neck cancer and experienced a partial response. Conclusion: ABT-806i allows for real-time imaging of EGFR conformational expression in tumors, has an acceptable radiation dosimetry and provides important additional information about antigen expression compared to standard approaches using archival tissue. Its role to assist in patient selection for EGFR-based therapeutics and investigate treatment resistance should be further investigated.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25740
DOI: 10.2967/jnumed.120.253146
ORCID: 0000-0001-7319-8546
PubMed URL: 33509972
Type: Journal Article
Subjects: Biodistribution
EGFR
EGFRvIII
Monoclonal Antibodies
Oncology: General
SPECT
SPECT Imaging
Solid Tumors
Appears in Collections:Journal articles

Show full item record

Page view(s)

18
checked on May 6, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.